Anurag Singh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anurag Singh has a total of 206 co-authors. Here are the top co-authors by number of shared publications:
- Dominik Hartl
Department of Pediatrics I, University of Tübingen, Tübingen, Germany
9 shared publications Dominik Hartl
Universitätsklinik für Kinder-und Jugendmedizin, Tübingen, Germany
8 shared publicationsAndreas Hector
Department of Pediatrics I, University of Tuebingen, Tuebingen, Germany
6 shared publicationsIris Schäfer
Department of Pediatrics I, University of Tuebingen, Tuebingen, Germany
6 shared publicationsNikolaus Rieber
University Children’s Hospital, University of Tübingen
6 shared publicationsRupert Handgretinger
Department of Pediatrics I, University of Tuebingen, Tuebingen, Germany
6 shared publications
Latest Publications
- 1 May 2023
- Published by Oxford University Press (OUP)
- p. A3720
A Curious Case of Platypnea-Orthodeoxia Syndrome
- 1 May 2023
- Published by Oxford University Press (OUP)
- p. A3720
A Curious Case of Platypnea-Orthodeoxia Syndrome
- 26 October 2022
- Published by Georg Thieme Verlag KG in Hamostaseologie
- Vol. 42 (S 01) , S32-S37
Investigations to Assess the Impact of Syk-Inhibition on Antibody-Mediated Desialylation: Novel Implications on Therapy for Immune Thrombocytopenia
Immune thrombocytopenia (ITP) is an autoantibody-mediated bleeding disorder with an increased clearance of platelets and megakaryocyte dysfunction. Previously, we showed that antibody-induced desialylation plays a significant role in the pathophysiology of ITP, leading to impaired platelet adhesion and megakaryocyte differentiation via FcγRIIA.[1] In the current study, we aim to investigate whether spleen tyrosine kinase (Syk) inhibition can alter the platelet responses and desialylation, and improve the patient outcome in ITP. We aim to gain in-depth understanding of various aspects of Syk inhibition on human platelets, using a broad range of in vitro and ex vivo methods including flow cytometry, fluorescence microscopy, and calibrated automated thrombogram. To elucidate the role of FcyRIIA, anti-CD32 clone AT-10 was used followed by crosslinking with the secondary Fab2 antibody to stimulate the receptor. Activation of FcγRIIA resulted in a significant increase in platelet activation, apoptosis, and desialylation. Activated platelets were analyzed by CD62P and PAC1 expression and platelet apoptosis was determined as mitochondrial-transmembrane potential (Δψ) depolarization and phosphatidylserine externalization. Lectin binding to fluorescein-conjugated Ricinus communis agglutinin I was quantified to detect desialylation. Our data show that Syk inhibition can effectively alter antibody-mediated biological effects in ITP, which lead to platelet dysfunction via involvement of FcγRIIA. We were able to prevent antibody-mediated desialylation and impairment of platelet function, and platelet apoptosis in ITP via Syk inhibition. In ongoing studies, we explore the opportunity to restore impaired proplatelet formation by megakaryocytes with Syk inhibition and investigate the possibility of reverting desialylation in an established ex vivo model of thrombopoiesis. In summary, our data indicate that Syk inhibition might be a promising approach to prevent antibody-mediated platelet desialylation in ITP, and might serve as a potential therapeutic strategy to prevent patient complications during pathogenesis of ITP. Article published online: 26 October 2022 © 2022. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 26 October 2022
- Published by Georg Thieme Verlag KG in Hamostaseologie
- Vol. 42 (S 01) , S32-S37
Investigations to Assess the Impact of Syk-Inhibition on Antibody-Mediated Desialylation: Novel Implications on Therapy for Immune Thrombocytopenia
Immune thrombocytopenia (ITP) is an autoantibody-mediated bleeding disorder with an increased clearance of platelets and megakaryocyte dysfunction. Previously, we showed that antibody-induced desialylation plays a significant role in the pathophysiology of ITP, leading to impaired platelet adhesion and megakaryocyte differentiation via FcγRIIA.[1] In the current study, we aim to investigate whether spleen tyrosine kinase (Syk) inhibition can alter the platelet responses and desialylation, and improve the patient outcome in ITP. We aim to gain in-depth understanding of various aspects of Syk inhibition on human platelets, using a broad range of in vitro and ex vivo methods including flow cytometry, fluorescence microscopy, and calibrated automated thrombogram. To elucidate the role of FcyRIIA, anti-CD32 clone AT-10 was used followed by crosslinking with the secondary Fab2 antibody to stimulate the receptor. Activation of FcγRIIA resulted in a significant increase in platelet activation, apoptosis, and desialylation. Activated platelets were analyzed by CD62P and PAC1 expression and platelet apoptosis was determined as mitochondrial-transmembrane potential (Δψ) depolarization and phosphatidylserine externalization. Lectin binding to fluorescein-conjugated Ricinus communis agglutinin I was quantified to detect desialylation. Our data show that Syk inhibition can effectively alter antibody-mediated biological effects in ITP, which lead to platelet dysfunction via involvement of FcγRIIA. We were able to prevent antibody-mediated desialylation and impairment of platelet function, and platelet apoptosis in ITP via Syk inhibition. In ongoing studies, we explore the opportunity to restore impaired proplatelet formation by megakaryocytes with Syk inhibition and investigate the possibility of reverting desialylation in an established ex vivo model of thrombopoiesis. In summary, our data indicate that Syk inhibition might be a promising approach to prevent antibody-mediated platelet desialylation in ITP, and might serve as a potential therapeutic strategy to prevent patient complications during pathogenesis of ITP. Article published online: 26 October 2022 © 2022. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- Open Access
- 9 June 2022
- Published by American Society of Hematology in Blood
- Vol. 139 (23) , 3430-3438
The interaction between anti-PF4 antibodies and anticoagulants in vaccine-induced thrombotic thrombocytopenia
Life-threatening thrombotic events at unusual sites have been reported after vector-based vaccinations against severe acute respiratory syndrome coronavirus 2. This phenomenon is now termed vaccine-induced immune thrombotic thrombocytopenia (VITT). The pathophysiology of VITT is similar to that of heparin-induced thrombocytopenia (HIT) and is associated with platelet-activating antibodies (Abs) against platelet factor 4 (PF4). Therefore, current guidelines suggest nonheparin anticoagulants to treat VITT patients. In this study, we investigated the interactions of heparin, danaparoid, fondaparinux, and argatroban with VITT–Ab/PF4 complexes using an ex vivo model for thrombus formation as well as in vitro assays to analyze Ab binding and platelet activation. We found that immunoglobulin Gs (IgGs) from VITT patients induce increased adherent platelets/thrombus formation in comparison with IgGs from healthy controls. In this ex vivo flow-based model, the procoagulant activity of VITT IgGs was effectively inhibited with danaparoid and argatroban but also by heparin. Interestingly, heparin and danaparoid not only inhibited IgG binding to PF4 but were also able to effectively dissociate the preformed PF4/IgG complexes. Fondaparinux reduced the in vitro generation of procoagulant platelets and thrombus formation; however, it did not affect platelet aggregation. In contrast, argatroban showed no effect on procoagulant platelets and aggregation but significantly inhibited VITT-mediated thrombus formation. Taken together, our data indicate that negatively charged anticoagulants can disrupt VITT–Ab/PF4 interactions, which might serve as an approach to reduce Ab-mediated complications in VITT. Our results should be confirmed, however, in a clinical setting before a recommendation regarding the selection of anticoagulants in VITT patients could be made.
- 9 June 2022
- Published by American Society of Hematology in Blood
- Vol. 139 (23) , 3430-3438
Open AccessThe interaction between anti-PF4 antibodies and anticoagulants in vaccine-induced thrombotic thrombocytopenia
Life-threatening thrombotic events at unusual sites have been reported after vector-based vaccinations against severe acute respiratory syndrome coronavirus 2. This phenomenon is now termed vaccine-induced immune thrombotic thrombocytopenia (VITT). The pathophysiology of VITT is similar to that of heparin-induced thrombocytopenia (HIT) and is associated with platelet-activating antibodies (Abs) against platelet factor 4 (PF4). Therefore, current guidelines suggest nonheparin anticoagulants to treat VITT patients. In this study, we investigated the interactions of heparin, danaparoid, fondaparinux, and argatroban with VITT–Ab/PF4 complexes using an ex vivo model for thrombus formation as well as in vitro assays to analyze Ab binding and platelet activation. We found that immunoglobulin Gs (IgGs) from VITT patients induce increased adherent platelets/thrombus formation in comparison with IgGs from healthy controls. In this ex vivo flow-based model, the procoagulant activity of VITT IgGs was effectively inhibited with danaparoid and argatroban but also by heparin. Interestingly, heparin and danaparoid not only inhibited IgG binding to PF4 but were also able to effectively dissociate the preformed PF4/IgG complexes. Fondaparinux reduced the in vitro generation of procoagulant platelets and thrombus formation; however, it did not affect platelet aggregation. In contrast, argatroban showed no effect on procoagulant platelets and aggregation but significantly inhibited VITT-mediated thrombus formation. Taken together, our data indicate that negatively charged anticoagulants can disrupt VITT–Ab/PF4 interactions, which might serve as an approach to reduce Ab-mediated complications in VITT. Our results should be confirmed, however, in a clinical setting before a recommendation regarding the selection of anticoagulants in VITT patients could be made.
- Open Access
- 10 March 2022
- Published by American Society of Hematology in Blood
- Vol. 139 (10) , 1437-1438
Vaccinations and ITP: keep on track(ing)
In this issue of Blood, Lee et al report a retrospective analysis of the effects of SARS-CoV-2 vaccination on thrombocytopenia in patients with immune thrombocy
- 10 March 2022
- Published by American Society of Hematology in Blood
- Vol. 139 (10) , 1437-1438
Open AccessVaccinations and ITP: keep on track(ing)
In this issue of Blood, Lee et al report a retrospective analysis of the effects of SARS-CoV-2 vaccination on thrombocytopenia in patients with immune thrombocy
- Open Access
Immunosuppression in Malaria: Do Plasmodium falciparum Parasites Hijack the Host?
Malaria reflects not only a state of immune activation, but also a state of general immune defect or immunosuppression, of complex etiology that can last longer than the actual episode. Inhabitants of malaria-endemic regions with lifelong exposure to the parasite show an exhausted or immune regulatory profile compared to non- or minimally exposed subjects. Several studies and experiments to identify and characterize the cause of this malaria-related immunosuppression have shown that malaria suppresses humoral and cellular responses to both homologous (Plasmodium) and heterologous antigens (e.g., vaccines). However, neither the underlying mechanisms nor the relative involvement of different types of immune cells in immunosuppression during malaria is well understood. Moreover, the implication of the parasite during the different stages of the modulation of immunity has not been addressed in detail. There is growing evidence of a role of immune regulators and cellular components in malaria that may lead to immunosuppression that needs further research. In this review, we summarize the current evidence on how malaria parasites may directly and indirectly induce immunosuppression and investigate the potential role of specific cell types, effector molecules and other immunoregulatory factors.
Open AccessImmunosuppression in Malaria: Do Plasmodium falciparum Parasites Hijack the Host?
Malaria reflects not only a state of immune activation, but also a state of general immune defect or immunosuppression, of complex etiology that can last longer than the actual episode. Inhabitants of malaria-endemic regions with lifelong exposure to the parasite show an exhausted or immune regulatory profile compared to non- or minimally exposed subjects. Several studies and experiments to identify and characterize the cause of this malaria-related immunosuppression have shown that malaria suppresses humoral and cellular responses to both homologous (Plasmodium) and heterologous antigens (e.g., vaccines). However, neither the underlying mechanisms nor the relative involvement of different types of immune cells in immunosuppression during malaria is well understood. Moreover, the implication of the parasite during the different stages of the modulation of immunity has not been addressed in detail. There is growing evidence of a role of immune regulators and cellular components in malaria that may lead to immunosuppression that needs further research. In this review, we summarize the current evidence on how malaria parasites may directly and indirectly induce immunosuppression and investigate the potential role of specific cell types, effector molecules and other immunoregulatory factors.
- Open Access
- 19 March 2021
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 12
Expansion of Functional Myeloid-Derived Suppressor Cells in Controlled Human Malaria Infection
Malaria can cause life-threatening complications which are often associated with inflammatory reactions. More subtle, but also contributing to the burden of disease are chronic, often subclinical infections, which result in conditions like anemia and immunologic hyporesponsiveness. Although very frequent, such infections are difficult to study in endemic regions because of interaction with concurrent infections and immune responses. In particular, knowledge about mechanisms of malaria-induced immunosuppression is scarce. We measured circulating immune cells by cytometry in healthy, malaria-naïve, adult volunteers undergoing controlled human malaria infection (CHMI) with a focus on potentially immunosuppressive cells. Infectious Plasmodium falciparum (Pf) sporozoites (SPZ) (PfSPZ Challenge) were inoculated during two independent studies to assess malaria vaccine efficacy. Volunteers were followed daily until parasites were detected in the circulation by RT-qPCR. This allowed us to analyze immune responses during pre-patency and at very low parasite densities in malaria-naïve healthy adults. We observed a consistent increase in circulating polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC) in volunteers who developed P. falciparum blood stage parasitemia. The increase was independent of preceding vaccination with a pre-erythrocytic malaria vaccine. PMN-MDSC were functional, they suppressed CD4+ and CD8+ T cell proliferation as shown by ex-vivo co-cultivation with stimulated T cells. PMN-MDSC reduced T cell proliferation upon stimulation by about 50%. Interestingly, high circulating PMN-MDSC numbers were associated with lymphocytopenia. The number of circulating regulatory T cells (Treg) and monocytic MDSC (M-MDSC) showed no significant parasitemia-dependent variation. These results highlight PMN-MDSC in the peripheral circulation as an early indicator of infection during malaria. They suppress CD4+ and CD8+ T cell proliferation in vitro. Their contribution to immunosuppression in vivo in subclinical and uncomplicated malaria will be the subject of further research. Pre-emptive antimalarial pre-treatment of vaccinees to reverse malaria-associated PMN-MDSC immunosuppression could improve vaccine response in exposed individuals.
- 19 March 2021
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 12
Open AccessExpansion of Functional Myeloid-Derived Suppressor Cells in Controlled Human Malaria Infection
Malaria can cause life-threatening complications which are often associated with inflammatory reactions. More subtle, but also contributing to the burden of disease are chronic, often subclinical infections, which result in conditions like anemia and immunologic hyporesponsiveness. Although very frequent, such infections are difficult to study in endemic regions because of interaction with concurrent infections and immune responses. In particular, knowledge about mechanisms of malaria-induced immunosuppression is scarce. We measured circulating immune cells by cytometry in healthy, malaria-naïve, adult volunteers undergoing controlled human malaria infection (CHMI) with a focus on potentially immunosuppressive cells. Infectious Plasmodium falciparum (Pf) sporozoites (SPZ) (PfSPZ Challenge) were inoculated during two independent studies to assess malaria vaccine efficacy. Volunteers were followed daily until parasites were detected in the circulation by RT-qPCR. This allowed us to analyze immune responses during pre-patency and at very low parasite densities in malaria-naïve healthy adults. We observed a consistent increase in circulating polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC) in volunteers who developed P. falciparum blood stage parasitemia. The increase was independent of preceding vaccination with a pre-erythrocytic malaria vaccine. PMN-MDSC were functional, they suppressed CD4+ and CD8+ T cell proliferation as shown by ex-vivo co-cultivation with stimulated T cells. PMN-MDSC reduced T cell proliferation upon stimulation by about 50%. Interestingly, high circulating PMN-MDSC numbers were associated with lymphocytopenia. The number of circulating regulatory T cells (Treg) and monocytic MDSC (M-MDSC) showed no significant parasitemia-dependent variation. These results highlight PMN-MDSC in the peripheral circulation as an early indicator of infection during malaria. They suppress CD4+ and CD8+ T cell proliferation in vitro. Their contribution to immunosuppression in vivo in subclinical and uncomplicated malaria will be the subject of further research. Pre-emptive antimalarial pre-treatment of vaccinees to reverse malaria-associated PMN-MDSC immunosuppression could improve vaccine response in exposed individuals.
- Open Access
- 16 February 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (4) , 789
Primary Immune Thrombocytopenia: Novel Insights into Pathophysiology and Disease Management
Immune thrombocytopenia (ITP) is an autoimmune disorder defined by a significantly reduced number of platelets in blood circulation. Due to low levels of platelets, ITP is associated with frequent bruising and bleeding. Current evidence suggests that low platelet counts in ITP are the result of multiple factors, including impaired thrombopoiesis and variations in immune response leading to platelet destruction during pathological conditions. Patient outcomes as well as clinic presentation of the disease have largely been shown to be case-specific, hinting towards ITP rather being a group of clinical conditions sharing common symptoms. The most frequent characteristics include dysfunction in primary haemostasis and loss of immune tolerance towards platelet as well as megakaryocyte antigens. This heterogeneity in patient population and characteristics make it challenging for the clinicians to choose appropriate therapeutic regimen. Therefore, it is vital to understand the pathomechanisms behind the disease and to consider various factors including patient age, platelet count levels, co-morbidities and patient preferences before initiating therapy. This review summarizes recent developments in the pathophysiology of ITP and provides a comprehensive overview of current therapeutic strategies as well as potential future drugs for the management of ITP.
- 16 February 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (4) , 789
Open AccessPrimary Immune Thrombocytopenia: Novel Insights into Pathophysiology and Disease Management
Immune thrombocytopenia (ITP) is an autoimmune disorder defined by a significantly reduced number of platelets in blood circulation. Due to low levels of platelets, ITP is associated with frequent bruising and bleeding. Current evidence suggests that low platelet counts in ITP are the result of multiple factors, including impaired thrombopoiesis and variations in immune response leading to platelet destruction during pathological conditions. Patient outcomes as well as clinic presentation of the disease have largely been shown to be case-specific, hinting towards ITP rather being a group of clinical conditions sharing common symptoms. The most frequent characteristics include dysfunction in primary haemostasis and loss of immune tolerance towards platelet as well as megakaryocyte antigens. This heterogeneity in patient population and characteristics make it challenging for the clinicians to choose appropriate therapeutic regimen. Therefore, it is vital to understand the pathomechanisms behind the disease and to consider various factors including patient age, platelet count levels, co-morbidities and patient preferences before initiating therapy. This review summarizes recent developments in the pathophysiology of ITP and provides a comprehensive overview of current therapeutic strategies as well as potential future drugs for the management of ITP.
- 26 November 2020
- Published by Springer Nature
- Vol. 2236, 77-83
In Vitro Generation of Human Neutrophilic Myeloid-Derived Suppressor Cells
Myeloid-derived suppressor cells (MDSC) are a heterogeneous population of cells of myeloid origin. MDSC are functionally defined by their capacity to suppress T, NK, and B cell responses and henceforth altering the disease outcome in various pathological conditions. MDSC are further subdivided into three distinct subsets: monocytic (M-) MDSC, neutrophilic or polymorphonuclear (PMN-) MDSC, and early-stage (e-) MDSC. However, since surface markers utilized to define MDSC are expressed on other myeloid cells too, it is mandatory to functionally assess the suppressive activity for characterizing these cells. Here, we provide a protocol for generation of PMN-MDSC in vitro from freshly isolated human peripheral blood mononuclear cells. These MDSC can be used further to perform functional assays to determine their immunosuppressive potential or test their activities in various biological conditions, for instance in infection and cancer.
- 26 November 2020
- Published by Springer Nature
- Vol. 2236, 77-83
In Vitro Generation of Human Neutrophilic Myeloid-Derived Suppressor Cells
Myeloid-derived suppressor cells (MDSC) are a heterogeneous population of cells of myeloid origin. MDSC are functionally defined by their capacity to suppress T, NK, and B cell responses and henceforth altering the disease outcome in various pathological conditions. MDSC are further subdivided into three distinct subsets: monocytic (M-) MDSC, neutrophilic or polymorphonuclear (PMN-) MDSC, and early-stage (e-) MDSC. However, since surface markers utilized to define MDSC are expressed on other myeloid cells too, it is mandatory to functionally assess the suppressive activity for characterizing these cells. Here, we provide a protocol for generation of PMN-MDSC in vitro from freshly isolated human peripheral blood mononuclear cells. These MDSC can be used further to perform functional assays to determine their immunosuppressive potential or test their activities in various biological conditions, for instance in infection and cancer.
- Open Access
- 26 April 2019
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 10, 900
Myeloid-Derived Suppressor Cells in Lung Transplantation
Myeloid-derived suppressor cells (MDSC) are a heterogeneous group of immune cells from the myeloid lineage. MDSCs expand in pathological situations, such as chronic infection, cancer, autoimmunity, and allograft rejection. As chronic lung allograft dysfunction (CLAD) limits long-term survival after lung transplantation (LTx), MDSCs may play a role in its pathophysiology. We assessed phenotype and frequency of MDSCs in peripheral blood from lung transplant recipients and its relationship to post-transplant complications and immunosuppression. Granulocytic (G)-MDSC were identified and quantified by flow cytometry of blood from 4 control subjects and 20 lung transplant patients (stable n = 6, infection n = 5; CLAD n = 9). G-MDSC functionality was assessed in vitro by their capability to block CD4 and CD8 T cell proliferation. More G-MDSC could be assessed using EDTA tubes compared to heparin tubes (p = 0.004). G-MDSC were increased in stable lung transplant recipients vs. non-transplant controls (52.1% vs. 9.4%; p = 0.0095). The infection or CLAD groups had lower G-MDSCs vs. stable recipients (28.2%p = 0.041 and 33.0%; p = 0.088, respectively), but were not different among CLAD phenotypes. G-MDSC tended to correlate with cyclosporine A and tacrolimus levels (r2 = 0.18; r2 = 0.17). CD4 and CD8 cells proliferation decreased by 50 and 80% if co-cultured with MDSCs (1:6 and 1:2 MDSC:T-cell ratio, respectively). In conclusion, circulating MDSCs are measurable, functional and have a G-MDSC phenotype in lung transplant patients. Their frequency is increased in stable patients, decreased during post-transplant complications, and related to level of immunosuppression. This study may pave the way for further investigations of MDSC in the context of lung transplantation.
- 26 April 2019
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 10, 900
Open AccessMyeloid-Derived Suppressor Cells in Lung Transplantation
Myeloid-derived suppressor cells (MDSC) are a heterogeneous group of immune cells from the myeloid lineage. MDSCs expand in pathological situations, such as chronic infection, cancer, autoimmunity, and allograft rejection. As chronic lung allograft dysfunction (CLAD) limits long-term survival after lung transplantation (LTx), MDSCs may play a role in its pathophysiology. We assessed phenotype and frequency of MDSCs in peripheral blood from lung transplant recipients and its relationship to post-transplant complications and immunosuppression. Granulocytic (G)-MDSC were identified and quantified by flow cytometry of blood from 4 control subjects and 20 lung transplant patients (stable n = 6, infection n = 5; CLAD n = 9). G-MDSC functionality was assessed in vitro by their capability to block CD4 and CD8 T cell proliferation. More G-MDSC could be assessed using EDTA tubes compared to heparin tubes (p = 0.004). G-MDSC were increased in stable lung transplant recipients vs. non-transplant controls (52.1% vs. 9.4%; p = 0.0095). The infection or CLAD groups had lower G-MDSCs vs. stable recipients (28.2%p = 0.041 and 33.0%; p = 0.088, respectively), but were not different among CLAD phenotypes. G-MDSC tended to correlate with cyclosporine A and tacrolimus levels (r2 = 0.18; r2 = 0.17). CD4 and CD8 cells proliferation decreased by 50 and 80% if co-cultured with MDSCs (1:6 and 1:2 MDSC:T-cell ratio, respectively). In conclusion, circulating MDSCs are measurable, functional and have a G-MDSC phenotype in lung transplant patients. Their frequency is increased in stable patients, decreased during post-transplant complications, and related to level of immunosuppression. This study may pave the way for further investigations of MDSC in the context of lung transplantation.
- Open Access
- 19 December 2018
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 68 (4) , 673-685
MDSCs in infectious diseases: regulation, roles, and readjustment
Many pathogens, ranging from viruses to multicellular parasites, promote expansion of MDSCs, which are myeloid cells that exhibit immunosuppressive features. The roles of MDSCs in infection depend on the class and virulence mechanisms of the pathogen, the stage of the disease, and the pathology associated with the infection. This work compiles evidence supported by functional assays on the roles of different subsets of MDSCs in acute and chronic infections, including pathogen-associated malignancies, and discusses strategies to modulate MDSC dynamics to benefit the host.
- 19 December 2018
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 68 (4) , 673-685
Open AccessMDSCs in infectious diseases: regulation, roles, and readjustment
Many pathogens, ranging from viruses to multicellular parasites, promote expansion of MDSCs, which are myeloid cells that exhibit immunosuppressive features. The roles of MDSCs in infection depend on the class and virulence mechanisms of the pathogen, the stage of the disease, and the pathology associated with the infection. This work compiles evidence supported by functional assays on the roles of different subsets of MDSCs in acute and chronic infections, including pathogen-associated malignancies, and discusses strategies to modulate MDSC dynamics to benefit the host.